The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

IBI318 demonstrated a favorable safety profile and preliminary efficacy in treatment-naïve NSCLC and IO-naïve NPC patients. Further clinical studies are needed to assess the full therapeutic potential of PD-1/PD-L1 dual inhibition with bsAbs.

Authors

Institutions

Publication Details

Journal
Journal of Hematology & Oncology
Published
2024-11-29
DOI
https://doi.org/10.1186/s13045-024-01644-4
Citations
15
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
4.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

Hongyun Zhao, Wangjun Liao, Yuling Chen, Hong Pan et al.
15 citations
Journal of Hematology & Oncology
Cancer Immunotherapy and Biomarkers
4.24
article

The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

Hongyun Zhao, Wangjun Liao, Yuling Chen, Hong Pan, Yanqiu Zhao, Xiaoxiao Lu, Furong Liu, Dongmei Ji, Dingzhi Huang, Kunyu Yang, Hui Zhou, Jian Zhang, Xichun Hu, Dan-Yun Ruan, Xiao-Li Wei, Nong Xu, Wen Zhang
article en
15 citations

Abstract

IBI318 demonstrated a favorable safety profile and preliminary efficacy in treatment-naïve NSCLC and IO-naïve NPC patients. Further clinical studies are needed to assess the full therapeutic potential of PD-1/PD-L1 dual inhibition with bsAbs.

Journal of Hematology & OncologyVol. 17(1)
Union Hospital (HK), Shanghai Medical College of Fudan University (CN), Sun Yat-sen University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Sir Run Run Shaw Hospital (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Zhengzhou University (CN), Nanfang Hospital (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Huazhong University of Science and Technology (CN), Southern Medical University (CN), Zhejiang University (CN)
Innovent Biologics
Good health and well-being
Openalex Percentile: Top 4%
Cancer Immunotherapy and Biomarkers
4.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.